Is IQVIA Holdings Inc. (IQV) a Buy Post Earnings?

IQVIA Holdings Inc. (NYSE:IQV) is one of the best strong buy healthcare stocks to invest in. Mizuho cut the price target on IQVIA Holdings Inc. (NYSE:IQV) to $215 from $266 on February 23, reiterating an Outperform rating on the shares and updating its model on the company after the fiscal Q4 report. Truist also lowered the price target on the stock to $245 from $290 on February 19. It maintained a Buy rating on the shares, telling investors that it is updating its model on IQVIA Holdings Inc. (NYSE:IQV) after the re-segmentation following the company’s Q4 earnings, while also reducing its assumed forward EBITDA multiple to 13x from 14x to take into account the near-term AI disruption overhang.

In another development, TD Cowen cut the price target on IQVIA Holdings Inc. (NYSE:IQV) to $174 from $245 on February 17 and maintained a Hold rating on the shares. The firm updated its model following Q4 results and guidance, stating that while it believes risks from AI exist, it is crucial to note that they will play out over the long term, and the impact on CROs isn’t fully clear.

IQVIA Holdings Inc. (NYSE:IQV) provides advanced analytics, clinical research services, and technology solutions for the life sciences industry. Its operations are divided into Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions segments.

While we acknowledge the potential of IQV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.